Endocrine Abstracts (2017) 49 EP244 | DOI: 10.1530/endoabs.49.EP244

Neutrophil lymphocyte ratio in 6 month teriparatide therapy of osteoporosis

Bengur Taskiran1, Goknur Yorulmaz2, Guven Baris Cansu1 & Aysen Akalin2


1Yunus Emre State Hospital, Eskisehir, Turkey; 2Osmangazi University, Eskisehir, Turkey.


Aim: Low BMD and atherosclerosis may share similar underlying biological mechanisms including higher serum phosphate and inflammation. Neutrophil-lymphocyte ratio (NLR) as a simple marker of inflammation. There are scarce data indicating improved atherosclerosis and cardiovascular events with biphosphonate and teriparatide therapy. We aimed to evaluate NLR before and after 6 months of teriparatide therapy in patients with severe established osteoporosis.

Methods and materials: Electronic data of 53 (49 female, four male) patients with severe osteoporosis and history of fracture of femur neck and/or lumbar spine were evaluated. None of them were previously diagnosed with rheumatoid arthritis, DM, and secondary osteoporosis. Sixteen had with HT and/or other cardiovascular disease.

Results: Mean age was 74±9 years, baseline 25 OH vitamin D level 25.6±17.6 ng/ml, baseline NLR 2.22±0.89, 25 OH vitamin D level at 6th month 27.8±13.4 ng/ml, NLR at 6th month 2.10±0.96.

Mean baseline and 6th month measurements of NLR, 25 OH vitamin D, parathormone, ALP, ESR, and phosphorus were similar in patients with and without cardiovascular disease. NLR did not change significantly after 6 months of teriparatide therapy.

Conclusion: NLR does not change in short term teriparatide therapy and association between osteoporosis and cardiovascular disease cannot be settled in advanced age.

Article tools

My recent searches

No recent searches.